-
Posted by
Two Blokes May 22, 2025 -
Filed in
Stock
-
4 views
BIOVF is moving from legacy products to a six-asset strategic portfolio that's mostly centered on Haematology. In particular, its Haematology segment contributed 71.6% of BIOVF's Q1 revenues, and five of its six strategic drugs are in this segment. Gamifant is the only non-Haematology IP from its strategic portfolio. This Immunology drug accounted for roughly 9% of Q1 revenues and grew by approximately 31% YoY.
